Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834210 | 0.90 | KCNH2 (0.43) | GUSBKCNH2ALDH1A1KDM4EHPGD | |
| SCHEMBL2839962 | 0.90 | KCNH2 (0.43) | GUSBKCNH2ALDH1A1KDM4EHPGD | |
| SCHEMBL1104543 | 0.81 | YAP1 (0.43) | GUSBALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL2831509 | 0.80 | KCNH2 (0.46) | GUSBKCNH2ALDH1A1HPGDMAOB | |
| SCHEMBL2834323 | 0.78 | KCNH2 (0.52) | KCNH2MAOBPARP10 | |
| SCHEMBL2835599 | 0.78 | TP53 (0.48) | KCNH2ALDH1A1KDM4EMAOBTP53 | |
| SCHEMBL4830210 | 0.78 | TP53 (0.48) | KCNH2ALDH1A1KDM4EMAOBTP53 | |
| SCHEMBL2831540 | 0.74 | KCNH2 (0.51) | KCNH2ALDH1A1KDM4EMAOBPARP10 | |
| SCHEMBL2832438 | 0.74 | KCNH2 (0.51) | KCNH2ALDH1A1KDM4EMAOBPARP10 | |
| SCHEMBL841357 | 0.74 | KCNH2 (0.48) | KCNH2ALDH1A1KDM4EMAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | GUSB 797/4885KCNH2 3260/4885ALDH1A1 895/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | GUSB 4844/4885KCNH2 15/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.